Evidence map›Paper›PMID 27872237›Full record

ArticleInfection and immunity2017

Flagellin-Mediated Protection against Intestinal Yersinia pseudotuberculosis Infection Does Not Require Interleukin-22.

Rémi Porte, Laurye Van Maele, Natalia Muñoz-Wolf, Benoit Foligné, Laure Dumoutier, Julien Tabareau, Delphine Cayet, Pierre Gosset, Nicolas Jonckheere, Isabelle Van Seuningen and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Airway Administration of Flagellin Regulates the Inflammatory Response toAmerican journal of respiratory cell and molecular biology · 2021
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 3 countries.

Rémi PorteUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204, CIIL-Center for Infection and Immunity of Lille, Lille, France.
Laurye Van MaeleUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204, CIIL-Center for Infection and Immunity of Lille, Lille, France.
Natalia Muñoz-WolfLaboratory for Vaccine Research, Department of Biotechnology, Instituto de Higiene, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay.
Benoit FolignéUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204, CIIL-Center for Infection and Immunity of Lille, Lille, France.
Laure DumoutierLudwig Institute for Cancer Research, Brussels Branch, and de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.
Julien TabareauUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204, CIIL-Center for Infection and Immunity of Lille, Lille, France.
Delphine CayetUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204, CIIL-Center for Infection and Immunity of Lille, Lille, France.
Pierre GossetHopital Saint Vincent, Groupe Hospitalier de l'Institut Catholique de Lille, Université Catholique de Lille, Lille, France.
Nicolas JonckheereUniv. Lille, INSERM, CHU Lille, UMR-S 1172, JPArc-Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, Lille, France.
Isabelle Van SeuningenUniv. Lille, INSERM, CHU Lille, UMR-S 1172, JPArc-Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, Lille, France.
José A ChabalgoityLaboratory for Vaccine Research, Department of Biotechnology, Instituto de Higiene, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay.
Michel SimonetUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204, CIIL-Center for Infection and Immunity of Lille, Lille, France.
Mohamed LamkanfiDepartment of Medical Protein Research, VIB, and Department of Biochemistry, Ghent University, Ghent, Belgium.
Jean-Christophe RenauldLudwig Institute for Cancer Research, Brussels Branch, and de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.
Jean-Claude SirardUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204, CIIL-Center for Infection and Immunity of Lille, Lille, France.
Christophe CarnoyUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204, CIIL-Center for Infection and Immunity of Lille, Lille, France christophe.carnoy@univ-lille2.fr.
Centre Hospitalier Universitaire de Lille · FRInserm · FRCentre National de la Recherche Scientifique · FRUniversidad de la República · UYCenter for Infection and Immunity of Lille · FRGhent University · BELudwig Cancer Research · BEUCLouvain · BEUniversité Catholique de Lille · FRUniversité de Lille · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Signaling through Toll-like receptors (TLRs), the main receptors in innate immunity, is essential for the defense of mucosal surfaces. It was previously shown that systemic TLR5 stimulation by bacterial flagellin induces an immediate, transient interleukin-22 (IL-22)-dependent antimicrobial response to bacterial or viral infections of the mucosa. This process was dependent on the activation of type 3 innate lymphoid cells (ILCs). The objective of the present study was to analyze the effects of flagellin treatment in a murine model of oral infection with Yersinia pseudotuberculosis (an invasive, Gram-negative, enteropathogenic bacterium that targets the small intestine). We found that systemic administration of flagellin significantly increased the survival rate after intestinal infection (but not systemic infection) by Y. pseudotuberculosis This protection was associated with a low bacterial count in the gut and the spleen. In contrast, no protection was afforded by administration of the TLR4 agonist lipopolysaccharide, suggesting the presence of a flagellin-specific effect. Lastly, we found that TLR5- and MyD88-mediated signaling was required for the protective effects of flagellin, whereas neither lymphoid cells nor IL-22 was involved.

Indexed as

AnimalsDisease Models, AnimalFemaleFlagellinInterleukin-22InterleukinsIntestinal MucosaLipopolysaccharidesMiceMice, KnockoutRecombinant Fusion ProteinsSignal TransductionToll-Like ReceptorsYersinia pseudotuberculosisYersinia pseudotuberculosis InfectionsFlagellinInterleukin-22InterleukinsLipopolysaccharidesRecombinant Fusion ProteinsToll-Like Receptorsflagellininterleukin-22intestinemouse infectionTLR5Toll-like receptorsYersinia pseudotuberculosis

Identifiers

PMID27872237
PMCPMC5278166
OpenAlexW2556566405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.